---
title: "Mutation Analysis of Various Cancer Types"
format: 
  revealjs:
    css: styles.css
    slide-number: true
    tables:
      width: 100%
    tbl-cap-location: top
    slide-level: 2
    theme: default
    embed-resources: true
---

## Introduction/Background

-   Study with 1661 patients/samples
-   Main objective: New predictive biomarkers for Immune Checkpoint Inhibitors (ICI)
-   Examine the impact of Tumor Mutational Burden (TMB)
-   Higher TMB = Higher response?

## Materials

-   MSK-IMPACT -\> Next Generation Sequencing
-   3 versions: IMPACT 3 (341 genes), IMPACT 5 (410 genes), IMPACT 6 (468 genes)
-   Higher count of mutations detected as more genes are analysed
-   Datasets:
    -   data_clinical_patient.txt
    -   data_clinical_sample.txt
    -   data_gene_panel_matrix.txt
    -   data_mutations.txt
    -   data_sv.txt

![](../results/figures/mutation_count_IMPACT.png){.absolute top="170" left="30" width="400" height="400"}

## Methods

-   Survival Analysis:
    -   package : 'survival'
    -   Surv(): function object, parameters: survival time + status (dead or alive) of each patient
    -   survfit(): fits the object to the Kaplan Meier estimator.
    -   data used: clinical_patients
    -   result: step curve, each step indicates the status of patients per unit time. It can be stratified to different parameters (sex, age, cancer..)
-   Cox Regression:
    -   Hazard risk study from package: 'survival'
    -   $\lambda(t,j) = \lambda_0(t).\exp(\sum \beta_i X_i)$, $\lambda$ survival probability for individual $j_i$ at time t, $X_i$ the explanatory variables
    -   $\displaystyle \frac{\lambda(t,j_1)}{\lambda(t,j_2)} = \exp(\beta_i)$
-   Gene Set Enrichment Analysis
    -   GO Data from Molecular Signature Database
    -   Ranked list based on numbers of mutated Samples per Gene
    -   fgseaMultilevel() from fgsea package

## Results 1

-   Survival analysis - stratified by Cancer type ![](../results/figures/surv_count_per_gender_per_cancer.png){.absolute top="170" left="30" width="400" height="400"} ![](../results/figures/survival_cancer_type.png){.absolute top="170" left="30" width="400" height="400"}

-   Number of Mutations & SV per Cancer Type ![](../results/figures/SV_count_per_cancer.png){.absolute bottom="20" left="30" width="400" height="400"}

-   Mutation Type per Cancer Type
![](../results/figures/mutation_by_cancer.png){.absolute bottom="20" left="30" width="400" height="400"}

## Results 2

-   SV Analysis ![](../results/figures/SV_lengths_distribution.png){.absolute top="170" left="30" width="400" height="400"}

-   Number of SVs per Gene ![](../results/figures/SV_count_per_gene.png){.absolute top="170" right="30" width="400" height="400"}

## Results 3

-   EGFR per Cancer Type -\> Glioma ![](../results/figures/EGFR_count_per_cancer.png)

-   Overview Glioma

## Results 4

-   Survival Correlation with Co-founders(especially gender) ![](../results/figures/surv_plot_per_gender.png){.absolute top="170" left="30" width="400" height="400"}


-   Survival analysis on gender(subset glioma) ![](../results/figures/survival_glioma_gender.png){.absolute top="170" left="30" width="400" height="400"}
![](../results/figures/surv_plot_per_gender_for_glioma.png){.absolute top="170" left="30" width="400" height="400"}

## Results 5

::: text-block
-   Gene SV+ Mutation from Glioma

-   GSEA (SV) & Mutations
:::

::: table-small
| Biological Process | pvalue | adjusted pvalue |
|:-----------------------|-----------------------:|-----------------------:|
| [GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT]{style="color: red;"} | 1.874506e-06 | 0.0001852012 |
| GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS | 3.918503e-07 | 0.0001852012 |
| [GOBP_REGULATION_OF_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 8.078272e-07 | 0.0001852012 |
| GOBP_REGULATION_OF_CELLULAR_LOCALIZATION | 1.656334e-06 | 0.0001852012 |
| [GOBP_REGULATION_OF_MITOTIC_CELL_CYCLE_PHASE_TRANSITION]{style="color: blue;"} | 1.381711e-06 | 0.0001852012 |
| [GOBP_TUBE_DEVELOPMENT]{style="color: red;"} | 3.698399e-06 | 0.0003045015 |
| GOBP_CELLULAR_RESPONSE_TO_OXYGEN_LEVELS | 7.123257e-06 | 0.0003909877 |
| [GOBP_CELL_CYCLE_G1_S_PHASE_TRANSITION]{style="color: blue;"} | 6.760265e-06 | 0.0003909877 |
| [GOBP_REGULATION_OF_CELL_CYCLE_G1_S_PHASE_TRANSITION]{style="color: blue;"} | 6.408466e-06 | 0.0003909877 |
| [GOBP_MITOTIC_CELL_CYCLE_PHASE_TRANSITION]{style="color: blue;"} | 8.291796e-06 | 0.0004096147 |
| [GOBP_BLOOD_VESSEL_MORPHOGENESIS]{style="color: red;"} | 1.719120e-05 | 0.0007077046 |
| [GOBP_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 1.586304e-05 | 0.0007077046 |
| [GOBP_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 2.781322e-05 | 0.0010569024 |
| GOBP_CELL_AGING | 3.013967e-05 | 0.0010634999 |
| [GOBP_EXTRINSIC_APOPTOTIC_SIGNALING_PATHWAY]{style="color: green;"} | 3.409266e-05 | 0.0011227849 |
:::

## Discussion

-   Study

    -   Tumor burden

    -   higher TMB-\> higher survival

    -   more mutations no indication of severity of cancer

    -   Glioma only exemption, here no correlation?
